The Gut Onc Lab Podcast

Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal break down the blockbuster press release from Revolution Medicine regarding their Phase 3 trial, RASOLUTE 302. For years, KRAS was the "compact, smooth" molecule that defied targeted therapy, but the era of the molecular glue has officially arrived.            

Understanding the Breakthrough:

Chapters:

Drs. Hornstein, Brown, and Grewal discuss how Claudin 18.2 has quickly become an important actionable biomarker in upper GI cancers, with zolbetuximab now entering frontline treatment for selected HER2-negative, microsatellite-stable patients. They review the key phase 3 data supporting its use, while emphasizing that the major challenge in practice is managing the significant nausea and vomiting seen early in treatment. The conversation also highlights how biomarker sequencing now shapes therapy selection and how future strategies, including ADCs, CAR T-cell therapy, and immunotherapy combinations, may further expand the role of Claudin 18.2 targeting.

In the second episode of The Gut-Onc Collab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal tackle the explosive growth of targeted therapies in the Upper GI space. The team dives deep into the "how" and "when" of treating HER2-positive and HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinomas, moving from perioperative care to the second-line setting.

Key Takeaways:

From precision oncology to "triple-prophylaxis" anti-emetic strategies, this episode provides a roadmap for the modern management of Upper GI malignancies.

Chapters:

In this inaugural episode of The Gut Onc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down to break down the most impactful data from the 2026 ASCO GI Cancers Symposium. From bispecific antibodies in upper GI to the long-awaited "drugging" of KRAS in pancreatic cancer, the team discusses how these latest clinical findings are ready to move from the podium to the clinic.

Key highlights include:

Upper GI Advances: A deep dive into the HERIZON-GEA-01 trial and whether the zanidatamab triplet (Zani + Tislelizumab + Chemo) is ready to replace the current standard of care.

Claudin 18.2 Synergy: Early signals from the ILUSTRO trial combining zolbetuximab and nivolumab, and the practical challenges of managing infusion toxicities.

Pancreatic Cancer Breakthroughs: The "wild" 37% response rate of oral KRAS G12D inhibitors (INCB161734) in heavily pre-treated patients.

Whether you are a seasoned practitioner or a trainee, join the collab for a candid look at the "latest and greatest" in GI medical oncology.

Chapters: